(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 93.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.16%.
Abeona Therapeutics's revenue in 2026 is $25,520,000.On average, 10 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,254,399,591, with the lowest ABEO revenue forecast at $2,408,476,428, and the highest ABEO revenue forecast at $4,741,012,481. On average, 10 Wall Street analysts forecast ABEO's revenue for 2027 to be $7,422,485,407, with the lowest ABEO revenue forecast at $4,985,931,626, and the highest ABEO revenue forecast at $11,009,066,953.
In 2028, ABEO is forecast to generate $10,333,151,872 in revenue, with the lowest revenue forecast at $7,793,609,677 and the highest revenue forecast at $12,917,297,600.